Company profile for Orbsen Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Orbsen Therapeutics is a regenerative medicine company based in Galway, Ireland. Using proprietary technology, we are developing ground-breaking stromal cell treatments to address some of today’s most challenging diseases. Stromal cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes comp...
Orbsen Therapeutics is a regenerative medicine company based in Galway, Ireland. Using proprietary technology, we are developing ground-breaking stromal cell treatments to address some of today’s most challenging diseases. Stromal cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment potential is linked to the cells’ natural capacity to dampen inflammation and promote healing, repair and regeneration of damaged tissues.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Ireland
Address
Address
Orbsen Building, NUIG, University Road Galway
Telephone
Telephone
+353 (0) 91 528778
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmatimes.com/news/orbsen_announces_results_from_nephstrom_trial_1485975

PHARMATIMES
27 Jan 2023

https://www.prnewswire.com/news-releases/orbsen-therapeutics-announces-encouraging-interim-results-from-the-nephstrom-proof-of-concept-clinical-study-evaluating-orbcel-cell-therapy-in-patients-with-diabetes-and-advanced-chronic-kidney-disease-301730688.html

PR NEWSWIRE
26 Jan 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty